

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 4/05/2011

Members Present: Bill Origer MD Chair, Nicole O’Kane PharmD, Roger Citron BS Pharm, Tracy Klein FNP, Ruth Medak MD, Thad Mick PharmD

Members Absent: Rich Clark MD MPH

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:35pm. Meeting was held in room 104 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 3/08/2011. A motion to approve was made and passed unanimously.

3. Second Generation Antidepressants-new report: Dr. Origer directed the committee’s attention to the draft report “*Second Generation Antidepressants*” and the DERP report. The committee discussed the reports and developed conclusions.

Time was allotted for public testimony: None offered

Action: The committee unanimously voted to approve the Draft Report “*Second Generation Antidepressants*” as amended.

4. Next Meeting/Adjournment: There being no further business the meeting was adjourned by Chair Origer at 8:30pm. Topic for the next meeting will be the second generation antidepressants: clinician summary. Next scheduled meeting date 5/3/2011.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 3/08/2011

Members Present: Bill Origer MD Chair, Nicole O’Kane PharmD, Roger Citron BS Pharm, Tracy Klein FNP, Ruth Medak MD, Thad Mick PharmD

Members Absent: Rich Clark MD MPH

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:38pm. Meeting was held in room 104 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 2/08/2011. One typo was corrected and a motion to approve as amended was made and passed unanimously.

3. Atypical Antipsychotics-new report: Dr. Origer directed the committee’s attention to the draft report “*Atypical Antipsychotics*” and the DERP report. The committee discussed Conclusion 1 for Bipolar disorder as referred back by the HRC. The committee worked with the representative of AstraZeneca (Elham Tabarsi PharmD) to understand their comments and asked several questions. The Commission developed the following two statements to replace the original one:

1. There is insufficient evidence to determine a clinically meaningful difference between drugs in this class for bipolar disorder.
2. The strength of evidence for efficacy and comparative difference between drugs in this category is low

Time was allotted for public testimony: Testimony by Elham Tabarsi PharmD on behalf of AstraZeneca as above.

Action: The committee unanimously voted to approve the Draft Report “*Atypical Antipsychotics*” as amended.

4. Atypical Antipsychotics- Clinician Summary: Dr. Origer directed the committee’s attention to the draft Clinician Summary “*Atypical Antipsychotics*”. The committee made changes to include a drug that had been inadvertently left off of the original list, made grammatical corrections and changed the conclusions regarding Bipolar Disease to reflect the changes made earlier to the full HRC report on this topic.

Time was allotted for public testimony: None offered.

Action: The Committee unanimously approved the draft Clinician Summary “*Atypical Antipsychotics*”.

5. Next Meeting/Adjournment: There being no further business the meeting was adjourned by Chair Origer at 8:45pm. Topic for the next meeting will be the second generation antidepressants. Next scheduled meeting date 4/5/2011.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 2/08/2011

Members Present: Bill Origer MD Chair, Rich Clark MD MPH, Tracy Klein FNP, Ruth Medak MD, Thad Mick PharmD

Members Absent: Nicole O’Kane PharmD, Roger Citron BS Pharm.

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:35pm. Meeting was held in room 104 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 1/31/2011. A motion to approve was made and passed unanimously.

3. Atypical Antipsychotics-new report: Dr. Origer directed the committee’s attention to the draft report “*Atypical Antipsychotics*” and the DERP report. The committee continued and completed its development of conclusions.

Time was allotted for public testimony.

Action: The committee unanimously voted to approve the Draft Report “*Atypical Antipsychotics*” as developed.

4. Next Meeting/Adjournment: There being no further business the meeting was adjourned by Chair Origer at 8:45pm. Topic for the next meeting will be development of a Clinician summary for the Atypical Antipsychotic class. Next scheduled meeting date 3/8/2011.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 1/31/2011

Members Present: Bill Origer MD Chair, Rich Clark MD MPH, Tracy Klein FNP, Ruth Medak MD, Nicole O’Kane PharmD, Thad Mick PharmD

Members Absent: None

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:36pm. Meeting was held in room 104 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 12/07/2010. A motion to approve was made and passed unanimously.

3. Atypical Antipsychotics-new report: Dr. Origer directed the committee’s attention to the draft “Clinician summary” report “*Atypical Antipsychotics*”. Dr. Origer made a presentation regarding the updated evidence in the DERP update. The committee discussed the report and began developing conclusions based on the evidence.

Time was allotted for public testimony. Jeana Colabianchi PharmD. Provided testimony on behalf of Sunovion Pharmaceuticals regarding a new drug that had just been approved in this category. The Committee thanked her for the information and stated that per HRC policy this new drug would be reviewed at the next HRC update when it had been incorporated into the next DERP update.

Action: None. The committee will continue discussions at the next meeting.

4. Next Meeting/Adjournment: There being no further business the meeting was adjourned by Chair Origer at 8:45pm. Next scheduled meeting date 3/8/2011.